Tariq Aldebasi1,2,3, Rabia Bashir1,2,3, Shiji Gangadharan1,2,3, Naila A Shaheen2,3, Basil Alhussain1,2,3, Tariq Almudhaiyan1,2,3, Bader Alahmari2,3,4. 1. Department of Ophthalmology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh 11426, Saudi Arabia. 2. King Abdullah International Medical Research Center (KAIMRC), Riyadh 11426, Saudi Arabia. 3. King Saud bin Abdulaziz University for Health Sciences, Riyadh 11426, Saudi Arabia. 4. Divisions of Adult Hematology and SCT, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh 11426, Saudi Arabia.
Abstract
AIM: To evaluate the incidence and severity of ocular graft versus host disease (oGVHD) in patients who underwent allogeneic stem cell transplant (SCT) in King Abdul-Aziz Medical City, Saudi Arabia. METHODS: This is a retrospective cohort study conducted in King Abdul Aziz Medical City on patients who underwent allogeneic hematopoietic cell transplant (allo-HCT) from 2010 to 2017. The ocular examination findings including visual acuity, meibomian gland dysfunction, corneal and conjunctival staining with severity, corneal scarring, tear film meniscus and breakup time, anterior and posterior segment examination findings, intraocular pressure, treatment given, punctual plugs used or not, and follow up response were collected. RESULTS: The five years cumulative incidence of oGVHD among post-transplant patients was 56.98% (95%CI 38.6%-71.7%). The potential risk factors assessed for developing ocular manifestation were age, gender, donor's age, donor gender mismatch CD3 and CD34 infusion, while none of the correlates were identified as statistically significant risk factors of developing ocular manifestation. However, the incidence was statistically significantly different between patients diagnosed with acute myelocytic leukemia and acute lymphocytic leukemia (P=0.038). The mean latent period to develop ocular symptoms was 20.5mo. All patients had variable degree of dry eyes. None of the patients developed any posterior segment complication. CONCLUSION: The incidence of oGVHD is low in King Abdul-Aziz Medical City. This can be attributed to the preconditioning and immunosuppressive regime. International Journal of Ophthalmology Press.
AIM: To evaluate the incidence and severity of ocular graft versus host disease (oGVHD) in patients who underwent allogeneic stem cell transplant (SCT) in King Abdul-Aziz Medical City, Saudi Arabia. METHODS: This is a retrospective cohort study conducted in King Abdul Aziz Medical City on patients who underwent allogeneic hematopoietic cell transplant (allo-HCT) from 2010 to 2017. The ocular examination findings including visual acuity, meibomian gland dysfunction, corneal and conjunctival staining with severity, corneal scarring, tear film meniscus and breakup time, anterior and posterior segment examination findings, intraocular pressure, treatment given, punctual plugs used or not, and follow up response were collected. RESULTS: The five years cumulative incidence of oGVHD among post-transplant patients was 56.98% (95%CI 38.6%-71.7%). The potential risk factors assessed for developing ocular manifestation were age, gender, donor's age, donor gender mismatch CD3 and CD34 infusion, while none of the correlates were identified as statistically significant risk factors of developing ocular manifestation. However, the incidence was statistically significantly different between patients diagnosed with acute myelocytic leukemia and acute lymphocytic leukemia (P=0.038). The mean latent period to develop ocular symptoms was 20.5mo. All patients had variable degree of dry eyes. None of the patients developed any posterior segment complication. CONCLUSION: The incidence of oGVHD is low in King Abdul-Aziz Medical City. This can be attributed to the preconditioning and immunosuppressive regime. International Journal of Ophthalmology Press.
Authors: Michael A Spinner; Marcelo Fernández-Viña; Lisa E Creary; Olivia Quinn; Linda Elder; Sally Arai; Laura J Johnston; Everett H Meyer; David B Miklos; Lori S Muffly; Robert S Negrin; Judith A Shizuru; Wen-Kai Weng; Ginna G Laport; Samuel Strober; Robert Lowsky; Andrew R Rezvani Journal: Blood Adv Date: 2017-07-25
Authors: A Tichelli; T Duell; M Weiss; G Socié; P Ljungman; A Cohen; M van Lint; A Gratwohl; H J Kolb Journal: Bone Marrow Transplant Date: 1996-06 Impact factor: 5.483
Authors: Theresa Hahn; Philip L McCarthy; Anna Hassebroek; Christopher Bredeson; James L Gajewski; Gregory A Hale; Luis M Isola; Hillard M Lazarus; Stephanie J Lee; Charles F Lemaistre; Fausto Loberiza; Richard T Maziarz; J Douglas Rizzo; Steven Joffe; Susan Parsons; Navneet S Majhail Journal: J Clin Oncol Date: 2013-05-28 Impact factor: 44.544
Authors: Yoshihiro Inamoto; Igor Petriček; Nuria Valdés-Sanz; Linda Burns; Saurabh Chhabra; Zack DeFilipp; Peiman Hematti; Alicia Rovó; Raquel Schears; Ami Shah; Vaibhav Agrawal; Aisha Al-Khinji; Ibrahim Ahmed; Asim Ali; Mahmoud Aljurf; Hassan Alkhateeb; Amer Beitinjaneh; Neel Bhatt; Dave Buchbinder; Michael Byrne; Natalie Callander; Kristina Fahnehjelm; Nosha Farhadfar; Robert Peter Gale; Siddhartha Ganguly; Gerhard C Hildebrandt; Erich Horn; Ann Jakubowski; Rammurti T Kamble; Jason Law; Catherine Lee; Sunita Nathan; Olaf Penack; Ravi Pingali; Pinki Prasad; Drazen Pulanic; Seth Rotz; Aditya Shreenivas; Amir Steinberg; Khalid Tabbara; André Tichelli; Baldeep Wirk; Jean Yared; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw Journal: Bone Marrow Transplant Date: 2019-02-27 Impact factor: 5.483